Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Nov 06, 2023 8:10pm
208 Views
Post# 35720549

RE:RE:RE:pre-BTD and BTD

RE:RE:RE:pre-BTD and BTD
It is definitely a bit of a guess but based on the fact that in the area I work we tend to put emphasis on having a total of 1 yr follow up from the last "treatment". Maint at 6m means that following to 18m is what would be ideal.

The recent trial modification approval was interesting in that they asked Health Canada for approval to follow up a bit further on the CR patients and use a central pathology lab to confirm results. It feels to me that that Health Canada request is in order to get data that they have been asked to put on the BTD application.

Yes, speculative. Doesn't change anything really other than helps explain what missing data is needed for BTD that they don't already have on files.

Regardless, I still believe in the science (management less so) and continue to hold.
<< Previous
Bullboard Posts
Next >>